美股A股
StockGist
Back
8-K2026-04-03· deepseek-chat

INDP · Indaptus Therapeutics, Inc.

0001493152-26-015079

SEC filing

Summary

Indaptus Therapeutics announced the resignation of CFO Nir Sassi and appointed Qinglai Lu to the Board and Audit Committee and Yu Ding as CFO, effective in early April 2026.

Key takeaways

Full analysis

The company is undergoing a leadership transition in its financial oversight and governance. The resignation of CFO Nir Sassi is noted as amicable, with no operational disagreements cited. His replacement, Yu Ding, brings over 20 years of financial experience, including recent roles as CFO for publicly traded companies on the Shanghai and Hong Kong Stock Exchanges, which may provide relevant expertise in navigating complex regulatory environments. Concurrently, the Board is adding Qinglai Lu, an independent director with extensive Asia-Pacific finance and investment experience, including roles at Plunkett Capital and Goldman Sachs, and appointing him to the Audit Committee alongside Jerome Jabbour. These changes refresh the company's financial leadership and audit oversight, though no compensatory arrangements for the new appointments are disclosed in the filing.